Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
0.00%
)
US TECH 100
28,487.60
(
0.46%
)
Dow Jones
49,526.17
(
0.00%
)
Brent Oil
105.29
(
-2.03%
)
Bitcoin
76,817.45
(
-0.76%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: acgood post# 122166

Thursday, 06/23/2011 8:26:49 AM

Thursday, June 23, 2011 8:26:49 AM

Post# of 257580
Re: MNTA FoB partnership

What about the possibility of the sequence of 1) PFE breakup into "innovative core pharma" company + ROW branded generic/legacy product +sell small parts...and then 2) then the noncore company partners with MNTA. This solves the conflict of interest discussed by Wheeler at GS.

Despite analyst reports touting the idea, I don’t expect PFE to split the “Established Products” (i.e. branded generics) business into a separate company.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today